Forum Archive Index - March 2000

[Nigel McCarter <n.mccarter@clear.net.nz>]

For those interested in the Biotech market should consider Medical
innovations (MIV)
The company's main product is a treatment for Psorias, (which Genesis is
also trying to treat).  But MIV has developed an ointment which is now past
clinical trial stage, whereas Genesis is using an immunisation approach.
Immunisation is grand, except that the development period will be
extensive.  In other words, MIV has a product just about ready for market
(see press release below) GEN has a protracted period of trials and
approvals yet to negotiate.
I've attached the latest press release below.

(I hold MIV)


>    NOTE: Half Yearly Report 99-00 has been posted  today 15/03/2000 on the
>MIL web site and is available as a PDF document for  viewing.   Below is
>separate ASX release dated  15/03/2000.    SUBSTANTIAL IMPROVEMENT AS 6
>MONTH LOSS HALVED; SALES SHOW STRONG GROWTH IN AUSTRALIA TRIALS OF SORAFIN
>OVERSEAS PLANNED MIV halved the 6 month loss to December 99, compared with
>the previous  corresponding December half-year; $370,000, compared with
>$776,000. AUSTRALIAN SALES GROWTH This resulted from9% sales growth
>overall, and reduced expenditure on trials  of MIV’s treatment for
>psoriasis, SORAFIN, during the half year. Sales in Australia grew strongly;
>up 16% on the previous period, reflecting  the success of the Strategic
>Alliance with Clinical Data, which replaced  MIV’s previous
>distributor in March 1999. The Alliance is now also  focusing on overseas
>sales. SORAFIN After successful trials of SORAFIN in late 1999 established
>its superiority   to the current most favoured treatment, directors are
>scheduled to visit  International Pharmaceutical Companies to continue
>discussions of co-ordinated  Stage III trials to satisfy regulatory
>requirements here and overseas.  Trials in Australia, originally planned to
>start earlier this year, will be  commenced after the overseas visit,  ""
>disease because of its unpleasant appearance. As a result of 
>disappointment with current treatments many sufferers adopt a fatalistic 
>approach and do not seek any treatment. In the USA alone there are more
>than 7  million sufferers, of whom a large majority do not use any of the
>therapeutic  treatments available at present. Sorafin also has the
>advantage of only sub-therapeutic levels of steroid  (0.01%) compared to
>the higher levels of the favoured treatment (0.05% to 0.1%)  a very
>important factor in treatment regimes, because of the side effects and 
>long term risks of long term use of higher dose steroids.  Yours Sincerely
>John Walsh Managing Director 
Nigel McCarter
Safety Management and Information Services Ltd
Box 23 019 Hamilton
Phone 64 7 858 2429 Fax 64 858 2689
Mobile 02 212 4901

----------------------------------------------------------------------------
http://www.sharechat.co.nz/          New Zealand's home for market investors
To remove yourself from this list, please us the form at
http://www.sharechat.co.nz/forum.html.